New medical technologies continue to be implicated in the rising costs of health carel-3 and some commentators argue that the sustainability of the National Health Service (NHS) depends partly on our ability to control their use4. One option is to control technology diffusion while research is conducted to assess clinical and cost effectiveness. However, the pressures for diffusion created by the media, public demand, manufacturers, professional enthusiasm and provider competitiveness make such control difficult. If technology adoption is to be managed appropriately in the public interest, then initiatives to strengthen the link between diffusion and clinical and economic evaluation must be effective and widely applied. This paper discusses how the ability to prioritize emerging technologies for assessment, undertake evaluative research and ensure that the results influence technology diffusion has been affected by recent changes in research and development policy and the separation of purchasers and providers in the NHS.
tend to include all health care interventions and methods of service delivery and are so broad that they can encompass a near-infinite variety of new drugs, services and interventions. Blanket statements that all new and emerging technologies should be controlled are too vague to be effective and a limited number should be identified for early evaluation and controlled diffusion.
The national Standing Group on Health Technologies (SGHT) has been prioritizing health care technologies for assessment since 1993. But recognition of the particular methodological problems of evaluating new and emerging technologies before they diffuse widely has led to two further initiatives. The National Co-ordinating Centre for Health Technology Assessment (NCCHTA) is undertaking 'horizon scanning' work to identify at an early stage those technologies which will affect health care outcomes and costs and have a substantial impact on the NHS7. This will improve the capacity to start evaluating emerging technologies as they are developed (although the difficulties of applying early research to policy are profound and are discussed further below).
Secondly, a Safety and Efficacy Register of New Interventional Procedures (SERNIP) has been established through which an advisory group of clinical and research experts will identify new surgical procedures, decide on the type of evaluation required and work to control their use until assessment has been completed8. The success of this process will depend on winning support and cooperation from clinicians, and close links between the advisory board and the Royal College should help to secure this. However, SERNIP's real strength lies in its focus on procedures rather than equipment. The former are often low cost, and are harder to identify and control than expensive equipment and services (on which most attention has been focused to date), but the cumulative cost of new high-volume procedures poses as great a dilemma to health policy makers as expensive equipment. UNDERTAKING EVALUATIVE RESEARCH ON NEW AND EMERGING TECHNOLOGIES The optimum research design will often be a randomized controlled trial, yet early trials of new technologies may be inappropriate for several reasons. Staff need to perfect their skill at using the intervention, patient selection has to be refined and patient numbers need to build up to economically viable levels9. Furthermore, new technologies tend to be dynamic such that many are still under development when introduced, and are refined in response to the experiences of early users10. Thus, trials might either underestimate or overestimate clinical and cost effectiveness if conducted too early, and observational studies, in the form of case series, represent an essential stage of assessment. Case series provide both preliminary information required for the design of methodologically more sophisticated research and the opportunity to modify and refine technologies and user skills before trials are undertaken. ' 'Pre-protocol research', the term increasingly used to describe such studies11, is often derided for its inherent biases and lack of methodological rigour. However, a recent NHS document recognized such research as appropriate for NHS Support Funding for Research and Development (R&D) so long as it had ethical approval, was conducted by experts and aimed to inform subsequent research with a more robust design' 2. Implementation of the Culyer Report has created a new national R&D funding stream for research in NHS organizations1l. The allocation of portfolio funding to recognized clinical research centres will provide some support for pre-protocol research on new technologies as well as the comparative studies and trials which follow. Additional research on high priority new technologies will also be commissioned through the NHS health technology assessment programme. However, increasing financial pressures on providers might hinder the early evaluation and longer-term monitoring of new technologies'3. The expense of such studies and follow-up of outcomes and side-effects has tended to blend into the costs of routine patient care. As these costs become more transparent, growing pressures on NHS trusts to meet efficiency targets and cut costs may limit the extent to which they are tolerated by hospital managers. Recent guidance from the NHS Executive states that trusts and purchasers must cover the patient care costs associated with R&D through normal commissioning arrangements'4. However, it remains to be seen whether purchasers who need to make savings on the value of their contracts will choose to fund research interventions and cut other services. Such difficulties could undermine efforts to evaluate selected high-priority new technologies. In response, Gray et al. 15 have proposed a regulatory framework to ensure purchaser and provider support for national research priorities.
Although the NHS technology assessment programme is improving the ability to conduct high-quality and timely health care evaluation, new and rapidly changing technologies still pose complex problems. Coordinated programmes of research on important new technologies may be needed, steered by a multidisciplinary advisory group. Uncontrolled observational research could be supported until larger comparative studies could usefully be conducted. Furthermore, the balance between efficacy research, subsequent pragmatic trials, reevaluation of changing technologies and longer term monitoring could be coordinated by the advisory group which could maintain an overview of available results and continuing information needs.
APPLYING RESEARCH TO POLICY ON THE USE OF NEW MEDICAL TECHNOLOGIES
If an appropriate balance between pre-protocol research, technologies can be achieved, results must then be used to influence policy i.e. widespread dissemination is essential. But current methods for research synthesis can discriminate against early studies which are unlikely to meet the selection criteria for systematic reviews, and randomized trials will not be available for meta-analysis. Early observational studies will initially provide the only information about effectiveness, and will be used by policy makers if no other information is available16. However, they are not routinely synthesized and distributed. Sculpher et al.17 have proposed an iterative process whereby early research is regularly reviewed and used to build computer models to aid decision making. Where gaps in research exist, they propose that expert opinion should be used to fill them until more results become available. Research summaries can be regularly updated and used to inform subsequent research design and for periodic reviews of policy on the use of specific technologies.
Disseminating research on new technologies is also difficult. Battista and Hodge'8 argue that, whilst decisions on high cost 'embodied' technologies are made by visible policy groups which are often receptive to research, the adoption of smaller technologies follows numerous decisions by a fragmented group of doctors who may be hostile to research. Even if research does reach a visible policy group, it is unlikely to be the only information that influences decisions about new technologies. An American study showed that technology assessments undertaken in hospitals focused primarily on the financial and organizational impact of technologies, whilst health maintenance organizations and third party payers paid more attention to safety, efficacy and effectiveness19. Where the diffusion of smaller technologies depends on numerous individual clinical decision makers, it is difficult to provide them with research summaries and even harder to ensure they use the results to inform decisions. THE 
PURCHASER-PROVIDER SPLIT AND MECHANISMS FOR THE CONTROL OF NEW AND EMERGING TECHNOLOGIES
Several mechanisms control the use of new and emerging technologies. The NHS global budget is acknowledged to restrict technology diffusion, albeit crudely so20. Special Medical Development Funds and national and regional planning mechanisms were used to control the diffusion of certain technologies, although with the abolition of NHS regions in 1996 their role in planning the introduction and location of selected high-cost equipment was devolved to districts. The NHS purchaser-provider split created the theoretical opportunity to use contracts to create financial incentives for research-linked diffusion. However, the way in which most contracts are drawn up has been too crude to clinical trials and longer-term monitoring of new Volume 91 J an u ary 1 9 98 influence technological innovation and existing incentives have related more to provider activity levels than to effectiveness21.
Centrally coordinated attempts to improve the influence of purchasers on the use of certain new technologies have taken the form of NHS Executive Letters (ELs). These have been used to advise purchasers only to commission certain new technologies if used in conjunction with research22 and to control the use of expensive new drugs23. In addition, a report on small and specialist services (which are often host to new technologies) recommended the development of shared commissioning through purchasing consortia between districts24. However, a Clinical Standards Advisory Group report concluded that 'effective collaborative purchasing arrangements were seldom in place'25. This has led some purchasers to work more closely with providers to influence the use of new technologies rather than relying on market forces to create incentives for research-linked technology use. Local technology assessments have been commissioned26 and purchasers have negotiated with clinicians to develop research-linked guidance on the use of certain technologies27. These initiatives are consistent with the longer-term and more collaborative relationships between hospitals, health authorities, and locality commissioning groups with which the new Labour Government plans to replace the current contracting arrangements of the internal market28.
It seems likely that the division between health care providers and purchasers or commissioners of services will remain, albeit in a modified form under Labour. A move away from annual contracts will limit the opportunities for creating hard financial incentives to control new and emerging technologies, although there is little evidence to suggest that shorter-term contracts have been more effective than such collaborative arrangements. However, the negotiating powers of purchasers may also be constrained by a knowledge imbalance about new technologies which acts in favour of providers; by a lack of resources to undertake the sort of detailed commissioning required to control new technologies; or by other more political constraints on their actions. As a result, many decisions about introducing new technologies both large and small-are made within hospitals with negligible involvement of purchasers29.
RELATIONSHIPS BETWEEN TECHNOLOGY ASSESSORS AND TECHNOLOGY USERS
Within hospitals, doctors are rarely required to justify the acquisition and use of new technologies in terms of clinical and cost effectiveness. Proposals typically take the form of a business case, offering more detail on the probable financial and administrative impact of the technology than on clinical doctors to introduce new technologies in conjunction with continuous evaluation or monitoring of longer-term outcomes and there are rarely formal requirements within hospitals to review the use of a technology as new research emerges.
Hospital-based initiatives to improve clinical effectiveness are increasingly common, but tend to focus on established treatments for which a reasonable volume of research evidence already exists. A similar process is needed for reviewing research on new and emerging technologies. Examples of the integration of technology assessment into decisions about the use of new technologies can be seen in two American health care providers. At the Johns Hopkins University Hospital in Baltimore, an in-house technology assessment programme was established in 1986. Its remit includes the assessment of new and emerging technologies and findings can be fed directly to the hospital's decision makers30. In California, the non-academic Kaiser Permanente Group has both a new technology committee to assess complex, expensive or controversial technologies and a network of technology assessment groups attached to different clinical specialties31. In the latter, so-called clinical systems engineers (non-clinicians trained in technology assessment and critical appraisal of research literature) undertake technology assessments in response to clinician requests and continue to provide and update information on emerging evidence of effectiveness and developments in the technology after it has been introduced. Here, too, they work alongside clinicians, encouraging review of the clinical as well as the organizational effects of new technologies. There is ample scope to undertake similar work in UK hospitals and in primary care settings where secondary care services are now frequently commissioned. CONCLUSION There is no simple way to control the diffusion of new medical technologies while they are being evaluated, though the NCCHTA 'horizon scanning' programme, the establishment of SERNIP and methodological work on the evaluation of emerging technologies offer important national level initiatives to this end. It remains to be seen to what extent the new arrangements for funding NHS R&D can support the timely progression from pre-protocol studies of high priority new technologies to rigorous comparative trials and long-term monitoring. Aside from this, several further developments are needed to ensure that the link between evidence of clinical and cost effectiveness and technology diffusion becomes stronger.
First, a more flexible and iterative approach is needed to incorporate evolving research findings into policy on the early use of new technologies and to help design subsequent studies. Secondly, further initiatives are needed to ensure and cost effectiveness29. This does little to encourage that national priorities are acted upon at a local level. One approach might be through regulatory control of purchasers and providers as suggested by Gray et al.1s; another would be to increase the range of new technologies for which the Royal Colleges and other professional organizations negotiate clinician support for research-linked early use. Regular, iterative feedback on emerging evidence, details of further technological developments and interim recommendations on 'best practice' could be used as a way of sustaining the interest of clinicians, encouraging appropriate early use of new technologies and maintaining support for controlled diffusion.
Thirdly, the ability of purchasers (or commissioners) to create financial incentives to control or stimulate the use of new technologies must be enhanced to counter loss of the regional planning role, the limited success of inter-district purchasing consortia and the fragmentation of purchasing caused by general practitioner fundholding. The Clinical Standards Advisory Group report on specialist services (which are host to many new technologies) recommended that certain services should be purchased by bodies responsible for populations larger than those in districts25.
This would avoid duplication of technology assessment work; permit stronger market management; and enhance opportunities to use contracts to create financial incentives for evaluation.
Finally, decisions made within hospitals about new technologies could make more explicit use of existing research to define indications for use and identify further research questions. The 'effectiveness culture' which is developing quickly in many hospitals needs to expand to include new technologies and encourage in-house review of evidence to counter the current narrow business-case emphasis on their organizational and financial impact.
